US cannabis companies have endured a significant selloff in the days following the results of the election, seeing $2.6bn wiped off their collective market capitalization.
A new study concludes that conventional pharmaceutical manufacturers may benefit from investing in cannabis markets rather than lobbying against them.
The company has stated that the transaction has the potential to drive long-term value to Aurora’s existing cannabis business.
The company has reached the settlement following the suspension of shares on the AQSE stock exchange.
A new report suggests the market will grow at a CAGR of of 15.7 per cent during the forecast period of 2022 to 2028.
The company has provided an update on its activities.
“Most countries around Europe will be following the German lead,” writes Mike Sassano, CEO of Somai Pharmaceuticals.
The appointment will be made following suspension of the company’s shares from the AQSE.
The acquisition is a cornerstone of Halo’s shareholder value enhancement strategy, says CEO.
